PROK (ProKidney) ROE %: 0.00% (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

PROK ProKidney Corp PROK
25 GF Score
Price $1.62
! 2 Warning Signs
View Full Analysis

What is ProKidney ROE %?

ProKidney PROK 25 ROE % is 0.00% as of Mar. 2026. GuruFocus rates PROK with a GF Score™ of 25/100. The stock has 2 warning signs investors should review. Among 1,249 Biotechnology companies, ProKidney ranks worse than 80063.97% on this metric.

ROE % is calculated as Net Income divided by its average Total Stockholders Equity over a certain period of time. ProKidney's annualized net income for the quarter that ended in Mar. 2026 was $-80.15 Mil. ProKidney's average Total Stockholders Equity over the quarter that ended in Mar. 2026 was $-1,017.49 Mil. Therefore, ProKidney's annualized ROE % for the quarter that ended in Mar. 2026 was N/A%.

The historical rank and industry rank for ProKidney's ROE % or its related term are showing as below:

PROK's ROE % is not ranked *
in the Biotechnology industry.
Industry Median: -38.61
* Ranked among companies with meaningful ROE % only.

ProKidney  (NAS:PROK) ROE % Explanation

ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.

The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-80.148/-1017.49
=(Net Income / Revenue )*(Revenue / Total Assets)*(Total Assets / Total Stockholders Equity)
=(-80.148 / 0.904)*(0.904 / 314.179)*(314.179 / -1017.49)
=Net Margin %*Asset Turnover*Equity Multiplier
=-8865.93 %*0.0029*N/A
=ROA %*Equity Multiplier
=-25.71 %*N/A
=N/A %

With this breakdown, it is clear that if a company grows its Net Profit Margin, its Asset Turnover, or its Leverage, it can grow its ROE %.

The factors that affect a company's ROE % can also be illustrated with the five-step DuPont Analysis:

ROE %(Q: Mar. 2026 )
=Net Income/Total Stockholders Equity
=-80.148/-1017.49
=(Net Income / Pre-Tax Income) * (Pre-Tax Income / Operating Income) * (Operating Income / Revenue) * (Revenue / Total Assets) * (Total Assets / Total Stockholders Equity)
= (-80.148 / -170.484) * (-170.484 / -179.732) * (-179.732 / 0.904) * (0.904 / 314.179) * (314.179 / -1017.49)
= Tax Burden * Interest Burden * Operating Margin % * Asset Turnover * Equity Multiplier
= 0.4701 * 0.9485 * -19881.86 % * 0.0029 * N/A
=N/A %

Note: The net income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Net Income is used.

Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.


ProKidney ROE % Related Terms


ProKidney ROE % Historical Data

* Premium members only.

The historical data trend for ProKidney's ROE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

ProKidney ROE % Chart

ProKidney Annual Data
Trend Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROE %
Get a 7-Day Free Trial -299.86 0.00 0.00 0.00 0.00

ProKidney Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

PROK vs LXEO, CMPX, XFOR: ROE % Comparison

For the Biotechnology subindustry, ProKidney's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


ProKidney ROE % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, ProKidney's ROE % distribution charts can be found below:

* The bar in red indicates where ProKidney's ROE % falls into.


PROK
25GF Score
ProKidney Corp PROK
ROE % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

ProKidney ROE % Calculation

ProKidney's annualized ROE % for the fiscal year that ended in Dec. 2025 is calculated as

ROE %=Net Income (A: Dec. 2025 )/( (Total Stockholders Equity (A: Dec. 2024 )+Total Stockholders Equity (A: Dec. 2025 ))/ count )
=-68.986/( (-994.954+-1011.197)/ 2 )
=-68.986/-1003.0755
=N/A %

ProKidney's annualized ROE % for the quarter that ended in Mar. 2026 is calculated as

ROE %=Net Income (Q: Mar. 2026 )/( (Total Stockholders Equity (Q: Dec. 2025 )+Total Stockholders Equity (Q: Mar. 2026 ))/ count )
=-80.148/( (-1011.197+-1023.783)/ 2 )
=-80.148/-1017.49
=N/A %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2026) net income data. ROE % is displayed in the 30-year financial page.

* Note that if the average Total Stockholders Equity is zero or negative, then ROE % would be considered meaningless and hence not be calculated.

Frequently Asked Questions Learn more about ROE % →
What does a ROE % of 0.00% mean?
ProKidney (PROK) has a ROE % of 0.00% as of Mar. 2026. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ProKidney and its competitors. According to the industry distribution chart, ProKidney ranks #999999 out of 1249 companies in the Biotechnology industry.
Is ProKidney's ROE % too high?
ProKidney's current ROE % is 0.00%. Based on the distribution chart, ProKidney ranks #999999 out of 1249 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, ProKidney has a GF Score™ of 25/100, reflecting its overall financial health beyond just this single metric.
How does ProKidney's ROE % compare to LXEO and CMPX?
According to the Biotechnology industry distribution chart, ProKidney ranks #999999 out of 1249 companies for ROE %. This places ProKidney in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Biotechnology company?
A good ROE % depends on the Biotechnology industry context. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on ProKidney and its competitors. ProKidney's current ROE % is 0.00%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ProKidney stock overvalued right now?
ProKidney (PROK) has a current ROE % of 0.00%. The current ROE % is 0.00%. ProKidney's overall GF Score™ is 25/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For ProKidney (PROK), the current ROE % is 0.00% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

ProKidney Business Description

Other Exchanges PROK:Mexico
Address 2000 Frontis Plaza Boulevard, Suite 250, Winston-Salem, NC, USA, 27103
ProKidney Corp is a clinical-stage biotechnology company pioneering the development of a first-in-class, autologous cell therapy that is intended to preserve kidney function in patients with advance chronic kidney disease (CKD) and diabetes. Its product candidate, REACT (Renal Autologous Cell Therapy), is a disease-modifying cell therapy made from a patient's renal cells. REACT has the potential to slow and stabilize the progression of chronic kidney disease. The company's pipeline consists of the development program for severe diabetic kidney disease.
25GF Score

Get the complete analysis for PROK

ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.62
Price